BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
Last trade$85.36
Day change+$0.10 (+0.12%)
Day range$84.37 – $85.86
Volume658,487
Market cap$21.14B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for BNTX.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for BNTX.
Recent news
Company coverage with links to the original publishers.
Over 200 companies are advancing cancer vaccine development with 200+ pipeline candidates in clinical trials. Recent positive Phase III results for intismeran autogene (mRNA-4157) in melanoma and encouraging data for TG4050 in head and neck cancer are driving momentum. However, challenges including clinical efficacy uncertainties, manufacturing complexity, high production costs, and patient selection barriers remain obstacles to broader commercialization.
The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.
Moderna shares gained 3% following better-than-expected Q3 2026 earnings and raised full-year revenue guidance to 15-25% growth, driven by stronger international COVID-19 vaccine sales. The company's oncology pipeline, particularly its personalized cancer therapy intismeran developed with Merck, showed promising phase III results with a 42% reduction in recurrence or death risk. Despite premium valuation and ongoing cash burn concerns, Moderna maintains a Zacks Rank #2 (Buy) rating, supported by expanding respiratory vaccine portfolio and oncology opportunities.
BioNTech and Moderna are transitioning from pandemic-era COVID-19 vaccine dominance to sustainable businesses through oncology and other disease pipelines. BioNTech is favored for 2027 due to its stronger financial position (€16.2 billion cash, zero debt, positive cash flow) and expanding cancer treatment pipeline, while Moderna faces greater financial pressure from declining vaccine revenue despite promising late-stage cancer vaccine results.
The article compares Bristol Myers Squibb (BMY) and Vertex Pharmaceuticals (VRTX) as investment options for 2027. BMY trades at a cheaper valuation (9.8x forward P/E) with a 4.06% dividend yield but faces revenue concentration risks and uncertain recovery timeline. VRTX commands a higher valuation (29.8x forward P/E) but demonstrates superior growth prospects, strong margins (85.61%), and successful product launches like Alyftrek. The author recommends Vertex as the better choice, citing its strong execution and growth momentum despite higher valuation multiples.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Jun 2, 2022
$2.1322
Jun 17, 2022
special
Stock splits
Historical share-structure events and their execution dates.